サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1419218

急性骨髄性白血病（AML）診断の世界市場 - 産業動向と予測（～2031年）

Global Acute Myeloid Leukemia Diagnostics Market - Industry Trends and Forecast to 2031
出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 406 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
急性骨髄性白血病（AML）診断の世界市場 - 産業動向と予測（～2031年）
出版日: 2023年12月01日
発行: Data Bridge Market Research
ページ情報: 英文 406 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の急性骨髄性白血病（AML）診断（AML）の市場規模は、2024年～2031年の予測期間にCAGRで11.3%の大幅に成長する見込みです。

当レポートでは、世界の急性骨髄性白血病（AML）診断市場について調査分析し、産業動向と予測、促進要因と抑制要因、企業情勢などの情報を提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

  • PESTEL分析
  • ポーターのファイブフォース分析
  • 疫学

第5章 世界の急性骨髄性白血病（AML）診断市場、規制

  • 米国の規制シナリオ
  • オーストラリアの規制シナリオ
  • 日本の規制シナリオ
  • 中国の規制シナリオ

第6章 市場の概要

  • 促進要因
    • 白血病がんの流行
    • 白血病診断における新たな技術の進歩
    • 予防健診の受診率の向上
    • 白血病がんに対する意識の高まり
  • 抑制要因
    • 白血病診断製品の承認と商品化に関する厳格な規制と基準
    • 白血病の診断の遅れと予後の悪化
  • 機会
    • 白血病を診断する製品の増加
    • がんの診断と治療に対する医療支出の増加
    • がん診断に対する政府の取り組み
  • 課題
    • コスト、安全性、利便性の問題の増加
    • 熟練した認定業者の不足

第7章 世界の急性骨髄性白血病（AML）診断市場：製品タイプ別

  • 概要
  • 器具
    • 生検器具
    • 病理学的器具
    • イメージング器具
    • その他
  • 消耗品・付属品
    • キット
    • 試薬
    • プローブ
    • その他の消耗品

第8章 世界の急性骨髄性白血病（AML）診断市場：検査タイプ別

  • 概要
  • 血液検査
    • 全血球計算（CBC）
    • 血液化学検査
    • その他
  • 画像検査
    • CTスキャン
    • MRI
    • PETスキャン
    • その他
  • 骨髄検査
    • 骨髄穿刺
    • 骨髄生検
    • その他
  • 遺伝子検査
    • 蛍光in situハイブリダイゼーション（FISH）
    • 核型分析
    • その他
  • バイオマーカー検査
    • 遺伝的AMLバイオマーカー
    • 後生的AMLバイオマーカー
    • プロテオミックAMLバイオマーカー
  • 免疫表現型解析
    • フローサイトメトリー
    • 免疫組織化学
    • その他
  • その他

第9章 世界の急性骨髄性白血病（AML）診断市場：がんタイプ別

  • 概要
  • 骨髄芽球性（M0）
  • 骨髄芽球性（M1）
  • 骨髄芽球性（M2）
  • 前骨髄球性（M3）
  • 骨髄単球性（M4）
  • 単球性（M5）
  • 赤白血病（M6）
  • 巨核芽球性（M7）

第10章 世界の急性骨髄性白血病（AML）診断市場：年齢層別

  • 概要
  • 65歳以上
  • 30～65歳
  • 21歳未満
  • 21～29歳

第11章 世界の急性骨髄性白血病（AML）診断市場：性別

  • 概要
  • 男性
  • 女性

第12章 世界の急性骨髄性白血病（AML）診断市場：エンドユーザー別

  • 概要
  • 病院
  • 関連研究所
  • 独立診断研究所
  • 画像診断センター
  • がん研究機関
  • その他

第13章 世界の急性骨髄性白血病（AML）診断市場：流通チャネル別

  • 概要
  • 直接提供
  • 小売販売

第14章 世界の急性骨髄性白血病（AML）診断市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • ロシア
    • オランダ
    • スイス
    • ベルギー
    • トルコ
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • インドネシア
    • フィリピン
    • タイ
    • マレーシア
    • ベトナム
    • シンガポール
    • その他のアジア太平洋
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • エジプト
    • イスラエル
    • その他の中東・アフリカ

第15章 世界の急性骨髄性白血病（AML）診断市場：企業情勢

  • 企業シェア分析：世界
  • 企業シェア分析：北米
  • 企業シェア分析：欧州
  • 企業シェア分析：アジア太平洋

第16章 SWOT分析

第17章 企業プロファイル

  • CANON MEDICAL SYSTEMS CORPORATION.
  • SYSMEX CORPORATION
  • EPIGENOMICS AG.
  • MYRIAD GENETICS, INC.
  • F. HOFFMANN-LA ROCHE LTD
  • ABBOTT
  • AGILENT TECHNOLOGIES, INC.
  • BD
  • BIOMERIEUX
  • BIO-RAD LABORATORIES, INC.
  • DIASORIN S.P.A.
  • EXACT SCIENCES CORPORATION
  • HOLOGIC INC.
  • ILLUMINA, INC.
  • KONINKLIJKE PHILIPS N.V.
  • MEDONICA CO. LTD
  • MINFOUND MEDICAL SYSTEMS CO., LTD
  • PLEXBIO
  • QIAGEN
  • QUEST DIAGNOSTICS INCORPORATED
  • SIEMENS HEALTHCARE GMBH
  • SONIC HEALTHCARE
  • STERNMED GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • TIME MEDICAL HOLDING

第18章 アンケート

第19章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 90
  • TABLE 2 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 97
  • TABLE 3 GLOBAL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 97
  • TABLE 4 GLOBAL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 97
  • TABLE 5 GLOBAL BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 98
  • TABLE 6 GLOBAL PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 99
  • TABLE 7 GLOBAL IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 100
  • TABLE 8 GLOBAL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 101
  • TABLE 9 GLOBAL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 101
  • TABLE 10 GLOBAL KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 102
  • TABLE 11 GLOBAL REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 103
  • TABLE 12 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 109
  • TABLE 13 GLOBAL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 109
  • TABLE 14 GLOBAL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 110
  • TABLE 15 GLOBAL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 111
  • TABLE 16 GLOBAL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 111
  • TABLE 17 GLOBAL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 112
  • TABLE 18 GLOBAL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 112
  • TABLE 19 GLOBAL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 113
  • TABLE 20 GLOBAL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 114
  • TABLE 21 GLOBAL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 115
  • TABLE 22 GLOBAL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 115
  • TABLE 23 GLOBAL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 116
  • TABLE 24 GLOBAL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 116
  • TABLE 25 GLOBAL OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 117
  • TABLE 26 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 122
  • TABLE 27 GLOBAL MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 122
  • TABLE 28 GLOBAL MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 123
  • TABLE 29 GLOBAL MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 123
  • TABLE 30 GLOBAL PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 124
  • TABLE 31 GLOBAL MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 124
  • TABLE 32 GLOBAL MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 125
  • TABLE 33 GLOBAL ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 125
  • TABLE 34 GLOBAL MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 126
  • TABLE 35 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 131
  • TABLE 36 GLOBAL 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 131
  • TABLE 37 GLOBAL 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 132
  • TABLE 38 GLOBAL BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 132
  • TABLE 39 GLOBAL 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 133
  • TABLE 40 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 138
  • TABLE 41 GLOBAL MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 138
  • TABLE 42 GLOBAL FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 139
  • TABLE 43 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 144
  • TABLE 44 GLOBAL HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 144
  • TABLE 45 GLOBAL ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 145
  • TABLE 46 GLOBAL INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 145
  • TABLE 47 GLOBAL DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 146
  • TABLE 48 GLOBAL CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 146
  • TABLE 49 GLOBAL OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 147
  • TABLE 50 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 152
  • TABLE 51 GLOBAL DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 152
  • TABLE 52 GLOBAL RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 153
  • TABLE 53 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 158
  • TABLE 54 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 159
  • TABLE 55 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 56 NORTH AMERICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 57 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 58 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 59 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 60 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 61 NORTH AMERICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 160
  • TABLE 62 NORTH AMERICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 161
  • TABLE 63 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 161
  • TABLE 64 NORTH AMERICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 161
  • TABLE 65 NORTH AMERICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 161
  • TABLE 66 NORTH AMERICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 67 NORTH AMERICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 68 NORTH AMERICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 69 NORTH AMERICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 70 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 71 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 163
  • TABLE 72 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 163
  • TABLE 73 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 163
  • TABLE 74 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 164
  • TABLE 75 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 76 U.S. INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 77 U.S. BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 78 U.S. PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 165
  • TABLE 79 U.S. IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
  • TABLE 80 U.S. CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
  • TABLE 81 U.S. KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
  • TABLE 82 U.S. REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
  • TABLE 83 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 84 U.S. BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 85 U.S. IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 86 U.S. BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 87 U.S. GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 88 U.S. BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 89 U.S. IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 90 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 91 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 169
  • TABLE 92 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 169
  • TABLE 93 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 169
  • TABLE 94 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 169
  • TABLE 95 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 170
  • TABLE 96 CANADA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 170
  • TABLE 97 CANADA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 170
  • TABLE 98 CANADA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 170
  • TABLE 99 CANADA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 100 CANADA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 101 CANADA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 102 CANADA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 103 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 104 CANADA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 105 CANADA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 106 CANADA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 107 CANADA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 108 CANADA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 109 CANADA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 110 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 111 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 174
  • TABLE 112 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 174
  • TABLE 113 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 174
  • TABLE 114 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 174
  • TABLE 115 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 116 MEXICO INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 117 MEXICO BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 118 MEXICO PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 175
  • TABLE 119 MEXICO IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
  • TABLE 120 MEXICO CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
  • TABLE 121 MEXICO KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
  • TABLE 122 MEXICO REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
  • TABLE 123 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 124 MEXICO BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 125 MEXICO IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 126 MEXICO BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 127 MEXICO GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 128 MEXICO BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 129 MEXICO IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 130 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 178
  • TABLE 131 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 179
  • TABLE 132 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 179
  • TABLE 133 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 179
  • TABLE 134 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 179
  • TABLE 135 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 180
  • TABLE 136 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 180
  • TABLE 137 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 180
  • TABLE 138 EUROPE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 181
  • TABLE 139 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 181
  • TABLE 140 EUROPE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 181
  • TABLE 141 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 181
  • TABLE 142 EUROPE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 182
  • TABLE 143 EUROPE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 182
  • TABLE 144 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 182
  • TABLE 145 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 182
  • TABLE 146 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 183
  • TABLE 147 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 183
  • TABLE 148 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 183
  • TABLE 149 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 183
  • TABLE 150 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 184
  • TABLE 151 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 184
  • TABLE 152 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 184
  • TABLE 153 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 184
  • TABLE 154 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 185
  • TABLE 155 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 185
  • TABLE 156 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
  • TABLE 157 GERMANY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
  • TABLE 158 GERMANY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
  • TABLE 159 GERMANY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
  • TABLE 160 GERMANY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 161 GERMANY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 162 GERMANY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 163 GERMANY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 187
  • TABLE 164 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 188
  • TABLE 165 GERMANY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 188
  • TABLE 166 GERMANY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 188
  • TABLE 167 GERMANY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 188
  • TABLE 168 GERMANY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 189
  • TABLE 169 GERMANY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 189
  • TABLE 170 GERMANY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 189
  • TABLE 171 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 189
  • TABLE 172 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 190
  • TABLE 173 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 190
  • TABLE 174 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 190
  • TABLE 175 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 190
  • TABLE 176 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 191
  • TABLE 177 UNITED KINGDOM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 191
  • TABLE 178 UNITED KINGDOM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 191
  • TABLE 179 UNITED KINGDOM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 191
  • TABLE 180 UNITED KINGDOM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 192
  • TABLE 181 UNITED KINGDOM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 192
  • TABLE 182 UNITED KINGDOM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 192
  • TABLE 183 UNITED KINGDOM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 192
  • TABLE 184 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 193
  • TABLE 185 UNITED KINGDOM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 193
  • TABLE 186 UNITED KINGDOM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 193
  • TABLE 187 UNITED KINGDOM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 193
  • TABLE 188 UNITED KINGDOM GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 189 UNITED KINGDOM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 190 UNITED KINGDOM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 191 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 194
  • TABLE 192 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 195
  • TABLE 193 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 195
  • TABLE 194 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 195
  • TABLE 195 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 195
  • TABLE 196 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 196
  • TABLE 197 FRANCE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 196
  • TABLE 198 FRANCE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 196
  • TABLE 199 FRANCE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 196
  • TABLE 200 FRANCE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 197
  • TABLE 201 FRANCE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 197
  • TABLE 202 FRANCE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 197
  • TABLE 203 FRANCE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 197
  • TABLE 204 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 198
  • TABLE 205 FRANCE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 198
  • TABLE 206 FRANCE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 198
  • TABLE 207 FRANCE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 198
  • TABLE 208 FRANCE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 199
  • TABLE 209 FRANCE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 199
  • TABLE 210 FRANCE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 199
  • TABLE 211 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 199
  • TABLE 212 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 200
  • TABLE 213 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 200
  • TABLE 214 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 200
  • TABLE 215 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 200
  • TABLE 216 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
  • TABLE 217 ITALY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
  • TABLE 218 ITALY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
  • TABLE 219 ITALY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
  • TABLE 220 ITALY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
  • TABLE 221 ITALY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
  • TABLE 222 ITALY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
  • TABLE 223 ITALY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 202
  • TABLE 224 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 225 ITALY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 226 ITALY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 227 ITALY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 203
  • TABLE 228 ITALY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 204
  • TABLE 229 ITALY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 204
  • TABLE 230 ITALY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 204
  • TABLE 231 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 204
  • TABLE 232 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 205
  • TABLE 233 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 205
  • TABLE 234 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 205
  • TABLE 235 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 205
  • TABLE 236 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 206
  • TABLE 237 SPAIN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 206
  • TABLE 238 SPAIN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 206
  • TABLE 239 SPAIN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 206
  • TABLE 240 SPAIN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 207
  • TABLE 241 SPAIN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 207
  • TABLE 242 SPAIN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 207
  • TABLE 243 SPAIN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 207
  • TABLE 244 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 208
  • TABLE 245 SPAIN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 208
  • TABLE 246 SPAIN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 208
  • TABLE 247 SPAIN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 208

LIST OF FIGURES

  • FIGURE 1 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 59
  • FIGURE 2 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DATA TRIANGULATION 62
  • FIGURE 3 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DROC ANALYSIS 63
  • FIGURE 4 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 64
  • FIGURE 5 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 64
  • FIGURE 6 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 66
  • FIGURE 7 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 67
  • FIGURE 8 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 68
  • FIGURE 9 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 69
  • FIGURE 10 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 73
  • FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD 74
  • FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2024 & 2031 74
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 75
  • FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD 76
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 84
  • FIGURE 16 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 86
  • FIGURE 17 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 86
  • FIGURE 18 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023 94
  • FIGURE 19 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION) 95
  • FIGURE 20 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2024-2031) 95
  • FIGURE 21 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 96
  • FIGURE 22 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023 106
  • FIGURE 23 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2024-2031 (USD MILLION) 107
  • FIGURE 24 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2024-2031) 107
  • FIGURE 25 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 108
  • FIGURE 26 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023 119
  • FIGURE 27 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2024-2031 (USD MILLION) 120
  • FIGURE 28 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2024-2031) 120
  • FIGURE 29 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 121
  • FIGURE 30 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023 128
  • FIGURE 31 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION) 129
  • FIGURE 32 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2024-2031) 129
  • FIGURE 33 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 130
  • FIGURE 34 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023 135
  • FIGURE 35 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2024-2031 (USD MILLION) 136
  • FIGURE 36 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2024-2031) 136
  • FIGURE 37 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 137
  • FIGURE 38 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023 141
  • FIGURE 39 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2024-2031 (USD MILLION) 142
  • FIGURE 40 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2024-2031) 142
  • FIGURE 41 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 143
  • FIGURE 42 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023 149
  • FIGURE 43 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 150
  • FIGURE 44 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 150
  • FIGURE 45 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 151
  • FIGURE 46 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2023) 156
  • FIGURE 47 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2023(%) 349
  • FIGURE 48 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 350
  • FIGURE 49 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 351
  • FIGURE 50 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 352
目次

Global acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 11.3% in the forecast period of 2024 to 2031. The new market report contains data for the historic year 2022, the base year of calculation is 2022, and the forecast period is 2024 to 2031.

Market Segmentation

Global Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments, and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), MONOCYTIC (M5), Erythroleukemia (M6) and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, 65, and Above), Gender (Male and Female) End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest Of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.

Driver

Increasing diagnostic products for leukemia cancer

Restraint

Late diagnosis and Poor prognosis of leukemia

Opportunity

Initiatives by government and other authorities for life sciences and funding

Market Players

Some of the major market players in the global acute myeloid leukemia diagnostics market are:

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN
  • Abbott
  • Siemens Healthcare GmbH
  • Hologic, Inc.
  • Agilent Technologies, Inc.
  • DiaSorin S.p.A.
  • Illumina, Inc.
  • BIOMERIEUX
  • Myriad Genetics, Inc.
  • Quest Diagnostics Incorporated.
  • Bio-Rad Laboratories, Inc.
  • Koninklijke Philips N.V.
  • BD
  • Exact Sciences Corporation
  • Time Medical Holding
  • PlexBio
  • MinFound Medical Systems Co., Ltd
  • Medonica Co. LTD
  • CANON MEDICAL SYSTEMS CORPORATION
  • Sysmex Corporation
  • Epigenomics AG
  • Sonic Healthcare
  • SternMed GmbH

TABLE OF CONTENTS

1 INTRODUCTION 53

  • 1.1 OBJECTIVES OF THE STUDY 53
  • 1.2 MARKET DEFINITION 53
  • 1.3 OVERVIEW OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 53
  • 1.4 LIMITATIONS 55
  • 1.5 MARKETS COVERED 56

2 MARKET SEGMENTATION 59

  • 2.1 MARKETS COVERED 59
  • 2.2 GEOGRAPHICAL SCOPE 60
  • 2.3 YEARS CONSIDERED FOR THE STUDY 61
  • 2.4 CURRENCY AND PRICING 61
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
  • 2.6 MULTIVARIATE MODELLING 65
  • 2.7 PRODUCT TYPE LIFELINE CURVE 65
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
  • 2.9 DBMR MARKET POSITION GRID 67
  • 2.10 MARKET END USER COVERAGE GRID 68
  • 2.11 VENDOR SHARE ANALYSIS 69
  • 2.12 SECONDARY SOURCES 70
  • 2.13 ASSUMPTIONS 70

3 EXECUTIVE SUMMARY 71

4 PREMIUM INSIGHTS 74

  • 4.1 PESTEL ANALYSIS 77
  • 4.2 PORTER'S FIVE FORCES 78
  • 4.3 EPIDEMIOLOGY 79

5 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 80

  • 5.1 REGULATORY SCENARIO IN THE U.S. 80
  • 5.2 REGULATORY SCENARIO IN AUSTRALIA 81
  • 5.3 REGULATORY SCENARIO IN JAPAN 81
  • 5.4 REGULATORY SCENARIO IN CHINA 81

6 MARKET OVERVIEW 83

  • 6.1 DRIVERS 85
    • 6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 85
    • 6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 87
    • 6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 87
    • 6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 88
  • 6.2 RESTRAINTS 88
    • 6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 88
    • 6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 89
  • 6.3 OPPORTUNITIES 89
    • 6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 89
    • 6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 90
    • 6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 91
  • 6.4 CHALLENGES 91
    • 6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 91
    • 6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 92

7 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 93

  • 7.1 OVERVIEW 94
  • 7.2 INSTRUMENTS 97
    • 7.2.1 BIOPSY INSTRUMENTS 98
      • 7.2.1.1 BONE MARROW BIOPSY 98
      • 7.2.1.2 NEEDLE BIOPSY 98
      • 7.2.1.3 SURGICAL BIOPSY 98
      • 7.2.1.4 OTHERS 98
    • 7.2.2 PATHOLOGY-BASED INSTRUMENTS 99
      • 7.2.2.1 PCR INSTRUMENTS 99
      • 7.2.2.2 SLIDE STAINING SYSTEMS 99
      • 7.2.2.3 TISSUE PROCESSING SYSTEMS 99
      • 7.2.2.4 CELL PROCESSORS 99
      • 7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 99
    • 7.2.3 IMAGING INSTRUMENTS 100
      • 7.2.3.1 ULTRASOUND SYSTEMS 100
      • 7.2.3.2 CT SYSTEMS 100
      • 7.2.3.3 MRI SYSTEMS 100
      • 7.2.3.4 OTHERS 100
    • 7.2.4 OTHERS 100
  • 7.3 CONSUMABLES & ACCESSORIES 101
    • 7.3.1 KITS 102
      • 7.3.1.1 PCR KITS 102
      • 7.3.1.2 DNA POLYMERASE KITS 102
      • 7.3.1.3 NUCLEIC ACID ISOLATION KITS 102
      • 7.3.1.4 OTHERS 102
    • 7.3.2 REAGENTS 103
      • 7.3.2.1 ASSAYS 103
      • 7.3.2.2 BUFFERS 103
      • 7.3.2.3 PRIMERS 103
      • 7.3.2.4 OTHERS 103
    • 7.3.3 PROBES 104
    • 7.3.4 OTHER CONSUMABLES 104

8 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 105

  • 8.1 OVERVIEW 106
  • 8.2 BLOOD TEST 109
    • 8.2.1 COMPLETE BLOOD COUNT (CBC) 110
    • 8.2.2 BLOOD CHEMISTRY TESTS 110
    • 8.2.3 OTHERS 110
  • 8.3 IMAGING TEST 111
    • 8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 111
    • 8.3.2 MRI 111
    • 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 112
    • 8.3.4 OTHERS 112
  • 8.4 BONE MARROW TESTS 112
    • 8.4.1 BONE MARROW ASPIRATE 113
    • 8.4.2 BONE MARROW BIOPSY 113
    • 8.4.3 OTHERS 113
  • 8.5 GENETIC TESTS 113
    • 8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 114
    • 8.5.2 KARYOTYPING 114
    • 8.5.3 OTHERS 114
  • 8.6 BIOMARKER TEST 115
    • 8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 115
    • 8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 115
    • 8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 116
  • 8.7 IMMUNOPHENOTYPING 116
    • 8.7.1 FLOW CYTOMETRY 116
    • 8.7.2 IMMUNOHISTOCHEMISTRY 117
    • 8.7.3 OTHERS 117
  • 8.8 OTHERS 117

9 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 118

  • 9.1 OVERVIEW 119
  • 9.2 MYELOBLASTIC (M0) 122
  • 9.3 MYELOBLASTIC (M1) 123
  • 9.4 MYELOBLASTIC (M2) 123
  • 9.5 PROMYELOCYTIC (M3) 124
  • 9.6 MYELOMONOCYTIC (M4) 124
  • 9.7 MONOCYTIC (M5) 125
  • 9.8 ERYTHROLEUKEMIA (M6) 125
  • 9.9 MEGAKARYOCYTIC (M7) 126

10 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 127

  • 10.1 OVERVIEW 128
  • 10.2 65 AND ABOVE 131
  • 10.3 30-65 132
  • 10.4 BELOW 21 132
  • 10.5 21-29 133

11 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 134

  • 11.1 OVERVIEW 135
  • 11.2 MALE 138
  • 11.3 FEMALE 139

12 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 140

  • 12.1 OVERVIEW 141
  • 12.2 HOSPITALS 144
  • 12.3 ASSOCIATED LABS 145
  • 12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 145
  • 12.5 DIAGNOSTIC IMAGING CENTERS 146
  • 12.6 CANCER RESEARCH INSTITUTES 146
  • 12.7 OTHERS 147

13 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 148

  • 13.1 OVERVIEW 149
  • 13.2 DIRECT TENDER 152
  • 13.3 RETAIL SALES 153

14 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 154

  • 14.1 OVERVIEW 155
  • 14.2 NORTH AMERICA 159
    • 14.2.1 U.S. 165
    • 14.2.2 CANADA 170
    • 14.2.3 MEXICO 175
  • 14.3 EUROPE 180
    • 14.3.1 GERMANY 186
    • 14.3.2 UNITED KINGDOM 191
    • 14.3.3 FRANCE 196
    • 14.3.4 ITALY 201
    • 14.3.5 SPAIN 206
    • 14.3.6 RUSSIA 211
    • 14.3.7 NETHERLANDS 216
    • 14.3.8 SWITZERLAND 221
    • 14.3.9 BELGIUM 226
    • 14.3.10 TURKEY 231
    • 14.3.11 REST OF EUROPE 236
  • 14.4 ASIA-PACIFIC 237
    • 14.4.1 CHINA 243
    • 14.4.2 JAPAN 248
    • 14.4.3 INDIA 253
    • 14.4.4 AUSTRALIA 258
    • 14.4.5 SOUTH KOREA 263
    • 14.4.6 INDONESIA 268
    • 14.4.7 PHILIPPINES 273
    • 14.4.8 THAILAND 278
    • 14.4.9 MALAYSIA 283
    • 14.4.10 VIETNAM 288
    • 14.4.11 SINGAPORE 294
    • 14.4.12 REST OF ASIA-PACIFIC 299
  • 14.5 SOUTH AMERICA 300
    • 14.5.1 BRAZIL 306
    • 14.5.2 ARGENTINA 311
    • 14.5.3 REST OF SOUTH AMERICA 316
  • 14.6 MIDDLE EAST AND AFRICA 317
    • 14.6.1 SOUTH AFRICA 323
    • 14.6.2 SAUDI ARABIA 328
    • 14.6.3 U.A.E 333
    • 14.6.4 EGYPT 338
    • 14.6.5 ISRAEL 343
    • 14.6.6 REST OF MIDDLE EAST AND AFRICA 348

15 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 349

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL 349
  • 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 350
  • 15.3 COMPANY SHARE ANALYSIS: EUROPE 351
  • 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 352

16 SWOT ANALYSIS 353

17 COMPANY PROFILES 354

  • 17.1 CANON MEDICAL SYSTEMS CORPORATION. 354
    • 17.1.1 COMPANY SNAPSHOT 354
    • 17.1.2 REVENUE ANALYSIS 355
    • 17.1.3 COMPANY SHARE ANALYSIS 355
    • 17.1.4 PRODUCT PORTFOLIO 356
    • 17.1.5 RECENT DEVELOPMENT 356
  • 17.2 SYSMEX CORPORATION 357
    • 17.2.1 COMPANY SNAPSHOT 357
    • 17.2.2 REVENUE ANALYSIS 357
    • 17.2.3 COMPANY SHARE ANALYSIS 358
    • 17.2.4 PRODUCT PORTFOLIO 358
    • 17.2.5 RECENT DEVELOPMENT 358
  • 17.3 EPIGENOMICS AG. 359
    • 17.3.1 COMPANY SNAPSHOT 359
    • 17.3.2 REVENUE ANALYSIS 359
    • 17.3.3 COMPANY SHARE ANALYSIS 360
    • 17.3.4 PRODUCT PORTFOLIO 360
    • 17.3.5 RECENT DEVELOPMENT 361
  • 17.4 MYRIAD GENETICS, INC. 362
    • 17.4.1 COMPANY SNAPSHOT 362
    • 17.4.2 REVENUE ANALYSIS 362
    • 17.4.3 COMPANY SHARE ANALYSIS 363
    • 17.4.4 PRODUCT PORTFOLIO 363
    • 17.4.5 RECENT DEVELOPMENT 364
  • 17.5 F. HOFFMANN- LA ROCHE LTD 365
    • 17.5.1 COMPANY SNAPSHOT 365
    • 17.5.2 REVENUE ANALYSIS 365
    • 17.5.3 COMPANY SHARE ANALYSIS 366
    • 17.5.4 PRODUCT PORTFOLIO 366
    • 17.5.5 RECENT DEVELOPMENT 366
  • 17.6 ABBOTT 367
    • 17.6.1 COMPANY SNAPSHOT 367
    • 17.6.2 REVENUE ANALYSIS 367
    • 17.6.3 PRODUCT PORTFOLIO 368
    • 17.6.4 RECENT DEVELOPMENT 368
  • 17.7 AGILENT TECHNOLOGIES, INC. 369
    • 17.7.1 COMPANY SNAPSHOT 369
    • 17.7.2 REVENUE ANALYSIS 369
    • 17.7.3 PRODUCT PORTFOLIO 370
    • 17.7.4 RECENT DEVELOPMENT 370
  • 17.8 BD 371
    • 17.8.1 COMPANY SNAPSHOT 371
    • 17.8.2 REVENUE ANALYSIS 371
    • 17.8.3 PRODUCT PORTFOLIO 372
    • 17.8.4 RECENT DEVELOPMENT 372
  • 17.9 BIOMERIEUX 373
    • 17.9.1 COMPANY SNAPSHOT 373
    • 17.9.2 PRODUCT PORTFOLIO 373
    • 17.9.3 RECENT DEVELOPMENT 373
  • 17.10 BIO-RAD LABORATORIES, INC. 374
    • 17.10.1 COMPANY SNAPSHOT 374
    • 17.10.2 REVENUE ANALYSIS 374
    • 17.10.3 PRODUCT PORTFOLIO 375
    • 17.10.4 RECENT DEVELOPMENT 375
  • 17.11 DIASORIN S.P.A. 376
    • 17.11.1 COMPANY SNAPSHOT 376
    • 17.11.2 REVENUE ANALYSIS 376
    • 17.11.3 PRODUCT PORTFOLIO 377
    • 17.11.4 RECENT DEVELOPMENTS 377
  • 17.12 EXACT SCIENCES CORPORATION 378
    • 17.12.1 COMPANY SNAPSHOT 378
    • 17.12.2 REVENUE ANALYSIS 378
    • 17.12.3 PRODUCT PORTFOLIO 379
    • 17.12.4 RECENT DEVELOPMENTS 379
  • 17.13 HOLOGIC INC. 380
    • 17.13.1 COMPANY SNAPSHOT 380
    • 17.13.2 REVENUE ANALYSIS 380
    • 17.13.3 PRODUCT PORTFOLIO 381
    • 17.13.4 RECENT DEVELOPMENT 381
  • 17.14 ILLUMINA, INC. 382
    • 17.14.1 COMPANY SNAPSHOT 382
    • 17.14.2 REVENUE ANALYSIS 382
    • 17.14.3 PRODUCT PORTFOLIO 383
    • 17.14.4 RECENT DEVELOPMENT 383
  • 17.15 KONINKLIJKE PHILIPS N.V. 384
    • 17.15.1 COMPANY SNAPSHOT 384
    • 17.15.2 REVENUE ANALYSIS 384
    • 17.15.3 PRODUCT PORTFOLIO 385
    • 17.15.4 RECENT DEVELOPMENT 385
  • 17.16 MEDONICA CO. LTD 386
    • 17.16.1 COMPANY SNAPSHOT 386
    • 17.16.2 PRODUCT PORTFOLIO 386
    • 17.16.3 RECENT DEVELOPMENT 386
  • 17.17 MINFOUND MEDICAL SYSTEMS CO., LTD 387
    • 17.17.1 COMPANY SNAPSHOT 387
    • 17.17.2 PRODUCT PORTFOLIO 387
    • 17.17.3 RECENT DEVELOPMENT 388
  • 17.18 PLEXBIO 389
    • 17.18.1 COMPANY SNAPSHOT 389
    • 17.18.2 PRODUCT PORTFOLIO 389
    • 17.18.3 RECENT DEVELOPMENTS 389
  • 17.19 QIAGEN 390
    • 17.19.1 COMPANY SNAPSHOT 390
    • 17.19.2 REVENUE ANALYSIS 390
    • 17.19.3 PRODUCT PORTFOLIO 391
    • 17.19.4 RECENT DEVELOPMENTS 391
  • 17.20 QUEST DIAGNOSTICS INCORPORATED 392
    • 17.20.1 COMPANY SNAPSHOT 392
    • 17.20.2 REVENUE ANALYSIS 392
    • 17.20.3 PRODUCT PORTFOLIO 393
    • 17.20.4 RECENT DEVELOPMENTS 393
  • 17.21 SIEMENS HEALTHCARE GMBH 394
    • 17.21.1 COMPANY SNAPSHOT 394
    • 17.21.2 REVENUE ANALYSIS 394
    • 17.21.3 PRODUCT PORTFOLIO 395
    • 17.21.4 RECENT DEVELOPMENT 395
  • 17.22 SONIC HEALTHCARE 396
    • 17.22.1 COMPANY SNAPSHOT 396
    • 17.22.2 PRODUCT PORTFOLIO 396
    • 17.22.3 RECENT DEVELOPMENT 396
  • 17.23 STERNMED GMBH 397
    • 17.23.1 COMPANY SNAPSHOT 397
    • 17.23.2 PRODUCT PORTFOLIO 397
    • 17.23.3 RECENT DEVELOPMENTS 397
  • 17.24 THERMO FISHER SCIENTIFIC INC. 398
    • 17.24.1 COMPANY SNAPSHOT 398
    • 17.24.2 REVENUE ANALYSIS 398
    • 17.24.3 PRODUCT PORTFOLIO 399
    • 17.24.4 RECENT DEVELOPMENT 399
  • 17.25 TIME MEDICAL HOLDING 400
    • 17.25.1 COMPANY SNAPSHOT 400
    • 17.25.2 PRODUCT PORTFOLIO 400
    • 17.25.3 RECENT DEVELOPMENT 401

18 QUESTIONNAIRE 402

19 RELATED REPORTS 406